Docetaxel 20mg Injection Exporter from India to USA – Ernest Oncology

Comprehensive Guide to Docelieva RTU 20mg Injection: Global Export & Distribution by Ernest Oncology

At Ernest Oncology (a division of Ernest Pharmaceutical Pvt. Ltd.), we are an internationally recognized exporter, bulk supplier, and distributor of critical oncology formulations. We specialize in the secure, compliant, and efficient supply of Docelieva RTU 20mg Injection to healthcare providers, hospitals, and pharmaceutical distributors worldwide, with targeted delivery networks in the USA, UK, Australia, and South Africa.

This comprehensive guide covers the medical profile, mechanisms, uses, and an extensive list of SEO keywords designed to boost the online visibility of B2B pharmaceutical suppliers.

1. What is Docelieva RTU 20mg Injection?

Docelieva RTU 20mg Injection (containing Docetaxel) is a potent, ready-to-use (RTU) anti-cancer medication that belongs to the taxoid class. It acts as an antimicrotubule agent designed to inhibit cell division and induce cell death (apoptosis) in rapidly dividing malignant cells.

Key Product Details

• Composition: Docetaxel (20 mg per vial).

• Therapeutic Class: Anti-neoplastic agent / Chemotherapeutic medication.

• Mechanism Class: Antimicrotubular inhibitor.

• Dosage Form: Concentrate for solution for intravenous (IV) infusion (Ready-To-Use).

2. Mechanism of Action

Docelieva RTU 20mg targets the structural framework of cancer cells through the following steps:

• Microtubule Stabilization: Microtubules are essential for cell division. Docetaxel binds to tubulin, promoting the assembly of microtubules while inhibiting their breakdown. This halts normal mitotic function.

• Mitotic Arrest: By preventing the microtubules from functioning correctly, the cell is locked in the G2/M phase of the cell cycle.

• Apoptosis: The inability of the cell to complete division triggers apoptosis, selectively killing malignant cells and halting tumor growth.

3. Therapeutic Indications and Uses

Docelieva RTU 20mg is indicated for the treatment of several solid tumors, often administered as part of a combination regimen or as a standalone agent:

• Breast Cancer: Used for both early-stage post-surgery treatment and metastatic or node-positive breast cancer.

• Prostate Cancer: Administered alongside prednisone for the treatment of metastatic castration-resistant prostate cancer.

• Non-Small Cell Lung Cancer (NSCLC): Administered alongside other platinum-based agents or as a single agent for advanced lung tumors.

• Gastric Adenocarcinoma: Used alongside cisplatin and fluorouracil.

• Squamous Cell Carcinoma of the Head and Neck (SCCHN): Used for induction treatment.

4. Administration and Storage

Administration

• Route: Administered exclusively via intravenous (IV) infusion under the supervision of an experienced oncologist or healthcare professional.

• Protocol: Usually given over a 1-hour period every three weeks.

• Pre-medication: Patients are typically pre-medicated with corticosteroids (such as dexamethasone) to reduce the severity of fluid retention and hypersensitivity reactions.

Storage and Handling

• Storage Temperature: Store at room temperature (between 15°C and 25°C). Do not freeze.

• Protect the vial from light and keep out of reach of children.

5. Potential Side Effects and Safety Warnings

• Common Side Effects: Low white blood cell counts (neutropenia), anemia, nausea, vomiting, fluid retention (edema), fatigue, muscle/joint pain, hair loss (alopecia), and peripheral neuropathy (tingling or numbness in hands and feet).

• Serious Risks: Myelosuppression, severe hypersensitivity reactions (swelling of the face, throat, and lips; difficulty breathing).

• Contraindications: Highly unsafe during pregnancy and lactation. The medication contains alcohol, which may be of concern for patients with alcohol-related disorders or liver issues. Regular blood monitoring is required.